Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Experts on follicular lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Experts on follicular lymphoma discuss first-line treatment options available for patients.

John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.

Initial induction therapy with the immunomodulatory agent lenalidomide plus the anti-CD20 monoclonal antibody rituximab led to prolonged, durable responses with a manageable safety profile in patients with previously untreated mantle cell lymphoma.

John N. Allan, MD, discusses a planned evaluation of obinutuzumab triplet consolidation therapy for patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who remain minimal residual disease–positive after initial treatment with zanubrutinib and venetoclax .

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

Scott Tagawa, MD, MS, FACP, discusses the evolution of antibody-drug conjugates in metastatic castration-resistant prostate cancer, as well as potential future targets for ADC development in this space.

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the possibility of expanding the use of supportive care regimens to reduce the effects of myelosuppression in patients with SCLC.

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, consider the broader impact of supportive care on cost burden and quality of life and share scenarios in which supportive care is most appropriate.

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, share insights about the value of patient-reported outcomes studies and the extent to which they can shape treatment decisions.

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, talk about factors to consider when weighing the risk/benefit ratio associated with the use of cyclin-dependent kinase 4/6 inhibition.